Yükleniyor... / Loading...
This study aims to develop a reliable calculation tool (a nomogram) that combines clinical and genetic information to help determine the correct dose of Warfarin, a blood thinner. Adults aged 18 and older who were about to start warfarin for conditions such as deep venous thrombosis, pulmonary embolism or atrial fibrillation were able to take part. Sponsored by Brigham and Women's Hospital, this study had no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: 1. Age ≥ 18 years old 2. Any newly diagnosed condition that will require treatment with therapeutic doses of warfarin for at least 4-6 weeks, e.g. deep venous thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), orthopedic surgery, etc. 3. Written informed consent Exclusion Criteria: 1. Current treatment with warfarin 2. Contraindication to therapeutic anticoagulation: * Active major bleeding * History of intracranial bleeding * Surgery, delivery, organ biopsy within 3 days * Gastrointestinal bleeding within 10 days * Major trauma within 3 days * Head injury requiring hospitalization within 3 months * Intracranial tumor * Neurosurgery or ophthalmologic surgery within the past month 3. Life expectancy \< 3 months 4. Pregnancy